You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
Scleroderma, myositis and related syndromes
FRI0402 Onset clinical involvement as prognostic factor in systemic sclerosis (SSC)
Free
  1. M Fernández Pestaña1,
  2. M Rubio Rivas1,
  3. C Tolosa Vilella2,
  4. A Guillén del Castillo3,
  5. D Argüelles Colunga4,
  6. L Trapiella Martinez5,
  7. V Fonollosa Pla3,
  8. CP Simeόn Aznar3,
  9. on behalf of RESCLE
  1. 1Internal Medicine Department, Hospital Universitario de Bellvitge, Barcelona
  2. 2Internal Medicine Department, Corporaciόn Sanitaria Universitaria Parc Taulí, Sabadell
  3. 3Autoinmune Diseases Unit. Internal Medicine Department, Hospital Vall d'Hebron, Barcelona
  4. 4Internal Medicine Department, Hospital Universitario Central de Asturias
  5. 5Internal Medicine Department, Hospital de Cabueñes, Oviedo, Spain

Abstract

Background In most patients with SSc, the onset is in the form of Raynaud's phenomenon (RP), but in a few is in the form of visceral or musculoskeletal involvement or skin sclerosis. Several risk factors are related to poor outcome in patients with SSc, but never before has the mode of onset been described as one of them.

Objectives To asses the mode of onset as prognostic factor in patients with SSc.

Methods A retrospective and multicentre cohort study including 1625 patients with SSc, based on the National Spanish Scleroderma Registry (RESCLE) which includes 28 referral centres.

RP, puffy hands, arthralgia/arthritis, skin sclerosis, intersititial lung disease (ILD), pulmonary arterial hypertension (PAH) and esophageal hipomotility where included as clinical modes of onset.

Results The cohort was split up in two groups: 1342 patients (83%) presented as RP and 283 (17%) presented as non-RP (see graphic below)

Non-RP patients where younger at onset of disease (44.7±16.5 vs 49±15.6 years, p<0.001), showed higher percentage of diffuse subtipe (36% vs 19%, p<0.001), developed more visceral involvement during the course of the illness and where more frequently anti-RNAp III positive (29 vs 10%, p<0.001).

View this table:

Risk factors for death. Univariate and multivariate analysis

Overall mortality was 16% in patients presented as RP vs 23% in non-RP patients (p=0.003). Few differences where noted among causes of death related to SSc, but the higher mortality was observed in RP group due to PAH (19% vs 8.1%, p=0.05) and due to ILD in non-RP group (24% vs 8.3%, p=0.002).

Survival of patients with RP at onset was better at anytime than those with a non-RP onset: 0.97 vs. 0.89 at 5 years, 0.93 vs. 0.82 at 10 years, 0.83 vs. 0.63 at 20 years and 0.71 vs. 0.51 at 30 years from onset (p<0.001).

Figure

Conclusions The mode of onset can be considered as independent prognostic factor, and specifically non-RP onset can be considered as a risk factor related to poorer outcome and RP onset and arthralgias can be considered as protector factors.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2017-eular.1675

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.